Anbio Biotechnology (NNNN)

NASDAQ: NNNN · USD

$3.81

+0.10 (+2.7%)· Recorded snapshot

Market cap	167.2M
Revenue (ttm)	8.6M
Net income (ttm)	6.4M
EPS (ttm)	$0.15
Shares out	43.9M
P/E (trailing)	26.0x
Volume	33,541

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 8.6M
Net income (ttm): 6.4M
EPS (ttm): $0.15
P/E (trailing): 26.0x
Market cap: 167.2M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Conserver

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/E26

P25 n/aP50 n/aP75 n/a

ROE27

P25 n/aP50 n/aP75 n/a

ROIC15.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All NNNN indicators

Market & fundamental data

Available fields

190

Groups with data

Currency

USD

Showing 190 of 190 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001982708
Company name	Anbio Biotechnology
Country	Germany
Country code	US
CUSIP number	G0367B105
Earnings date	2026-11-10
Earnings time	bmo
Employees	27
Enterprise value	$155.3M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2025-12-31
First seen	2026-05-09
Fiscal year end	December
Founded	2021
Industry	Medical Instruments & Supplies
IPO date	2025-02-19
Is primary listing	Yes
Is SPAC	No
ISIN number	KYG0367B1059
Last 10-K release date	2026-04-07
Last earnings date	2026-04-07
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$167.2M
Market cap category	Micro-Cap
Next earnings date	2026-11-10
Options	No
Price	$3.81
Price currency	USD
Sector	Healthcare
SIC code	2835
Stock price date	2026-10-28
Symbol	NNNN
Website	https://www.anbiobiotechnology.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	3.85%
EV/Earnings	23.13x
EV/EBIT	25.67x
EV/Sales	17.13x
FCF / EV yield	-4.55%
FCF yield	-4.21%
Graham number	1.50552
Graham upside	-58.7%
Industry forward P/E	22.69x
Industry P/E	75.18x
Lynch fair value	$0.73
Lynch upside	-79.89%
P/B ratio	5.4x
P/E ratio	25.98x
P/S ratio	18.5x
Price / tangible book value	5.31x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	66.7%
Gross margin	87.24%
Operating margin	66.7%
Pretax margin	74.06%
Profit margin	74.06%
Profit per employee	$237,165
Profitable years	4
Revenue per employee	$320,253
ROA	14.66%
ROCE	19.13%
ROE	27.05%
ROIC	15.23%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	161.33%
EPS growth (QoQ)	-32.09%
EPS growth years	1
Gross profit growth	28.17%
Gross profit growth (Q)	111.69%
Gross profit growth 3Y	-15.64%
Net income growth	169.87%
Net income growth (QoQ)	-31.39%
Net income growth 3Y	-13.84%
Net income growth years	2
Operating income growth	189.06%
Operating income growth (Q)	344.79%
Operating income growth 3Y	-17.3%
Revenue growth	5.64%
Revenue growth (Q)	73.93%
Revenue growth (QoQ)	-11.4%
Revenue growth 3Y	-28.39%
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	$5.8M
EPS	$0.15
FCF per share	$-0.15
Financing cash flow	$6.9M
Free cash flow	$-6.7M
Gross profit	$7.5M
Investing cash flow	$-4.2M
Net cash flow	$-4M
Net income	$6.4M
Operating income	$5.8M
Revenue	$8.6M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$0.69
Debt / equity	0
Long-term assets	$0
Long-term liabilities	$0
Net cash (debt)	$11.9M
Net cash / market cap	7.44%
Net cash growth	22.85%
Net debt / equity	-0.39
Piotroski F-Score	4
Shareholders' equity	$30.2M
Tangible book value	$30.2M
Tangible book value per share	$0.69
Total assets	$30.2M
Total cash	$11.9M
Total debt	$0
Total liabilities	$87,836

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.35
Current assets	$30.2M
Current liabilities	$87,836
Current ratio	344.31
Net working capital	$18.3M
Quick ratio	177.13
Working capital	$30.2M
Working capital turnover	0.39

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-3.27%
Dividend yield	0%
Shareholder yield	-3.27%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$15.19
1D price change	2.7%
1M price change	-38.89%
1M total return	-38.89%
1W price change	3.22%
1W total return	3.22%
1Y price change	-83.9%
1Y return CAGR	-83.92%
1Y total return	-83.9%
20-day SMA	$4.20
200-day SMA	$17.70
3M price change	-62.18%
3M total return	-62.18%
50-day SMA	$5.63
50-day SMA vs 200-day SMA	50under200
52-week high	$44.73
52-week high date	2025-12-05
52-week low	$3.09
52-week low date	2026-10-15
6M price change	-86.08%
6M total return	-86.08%
All-time high	$55.65
All-time high date	2025-07-15
All-time low	$3.09
All-time low date	2026-10-15
Average true range (ATR)	$0.54
Average volume	55K
Beta (1Y)	2.16
Beta (2Y)	1.75
Change from 52-week high	-91.48%
Change from 52-week low	23.3%
Change from all-time high	-93.08%
Change from all-time low	24.6%
Change from open	4.53%
Day's gap	-1.75%
Dollar volume	$127,791
High price	$3.86
Low price	$3.65
Monthly RSI	47.04
Open price	$3.65
Position in 52-week range	76.74%
Premarket change	0%
Premarket close	$3.71
Premarket price	$3.71
Previous close	$3.71
Price vs 150-day SMA	-74.65%
Price vs 20-day SMA	-8.25%
Price vs 200-day SMA	-78.24%
Price vs 50-day SMA	-31.59%
Relative volume	0.61
Return from IPO open	-30.7%
Return from IPO price	-27.1%
RSI	35.51
Sharpe ratio	-0.68
Sortino ratio	-0.98
Volume	33.5K
Weekly RSI	31.98
YTD price change	-87.2%
YTD total return	-87.2%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	39.7M
Float percentage	90.43%
Shares change (QoQ)	1.03%
Shares change (YoY)	3.27%
Shares held by institutions	0.3%
Shares outstanding	43.9M
Short % of float	0.14%
Short % of shares	0.12%
Short ratio	0.2 days

Deeper analysis on NNNN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this NNNN report

Is a complete NNNN research report available?

No complete published report is available for Anbio Biotechnology (NNNN) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Anbio Biotechnology (NNNN)

Price

Financial snapshot

Fair-value bridge

Latest news · NNNN

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NNNN indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on NNNN

Frequently asked questions